As a revolutionary biomedical technology, Cell and Gene Therapy (CGT) faces unique challenges in drug R&D, manufacturing processes, and clinical translation. These "living" drugs possess dynamic characteristics, which place higher demands on product quality research and safety evaluation, requiring the establishment of a rigorous quality control system throughout the entire R&D process. Leveraging its forward-looking layout and technical accumulation in the CGT field, Sequanta has established a comprehensive solution covering the entire drug R&D cycle. In the process development and quality control phase, the company provides core services such as vector integration site analysis, gene editing efficiency assessment (including on-target/off-target effect detection), and cell genomic stability monitoring; it also possesses robust capabilitiesin vector sequence release testing, as well as cell diferentiation characterization and population analysis. In the clinicalresearch stage, key studies such as cytokine immune response detection and in vivo cell distribution tracking can beconducted. By building a standardized technical service platform, Sequanta provides comprehensive technical support for CGT drugs from early R&D to commercial production, accelerating the translation of innovative therapies.
